» Articles » PMID: 8516620

Reversible Depletion of Synovial Lining Cells After Intra-articular Treatment with Liposome-encapsulated Dichloromethylene Diphosphonate

Overview
Journal Rheumatol Int
Specialty Rheumatology
Date 1993 Jan 1
PMID 8516620
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

We studied the depletion and repopulation of synovial lining cells in mice. A single intra-articular injection of liposomes encapsulating the drug dichloromethylene diphosphonate (CL2MDP) in the mouse knee joint caused selective elimination of synovial lining cells. Depletion of cells occurred within a few days as evidenced by light microscopic, electronmicroscopic and immunohistochemical studies. Maximal depletion was seen on day 7. Repopulation was observed in the following weeks, starting at the bone side of the joint. Until day 30, full recovery (60% recovery) was not observed in the lining lying adjacent to the dermis. Side effects on cartilage metabolism, such as inhibition of proteoglycan synthesis or degradation of proteoglycans from the matrix was minor but significant, 1 and 2 days after liposome treatment but thereafter full recovery was observed. Selective elimination of lining cells from the joint enabled us to study the in vivo role of these cells in the onset and subsequent pathology of experimental arthritis. An immune-complex-mediated experimental arthritis elicited in lining cell depleted joints that had received CL2MDP-liposomes 7 days earlier prevented inflammation as compared to controls.

Citing Articles

Recent advances in nanoparticle-based drug delivery systems for rheumatoid arthritis treatment.

Nasra S, Bhatia D, Kumar A Nanoscale Adv. 2022; 4(17):3479-3494.

PMID: 36134349 PMC: 9400644. DOI: 10.1039/d2na00229a.


The Rationale for the Intra-Articular Administration of Clodronate in Osteoarthritis.

Moretti A, Paoletta M, Liguori S, Ilardi W, Snichelotto F, Toro G Int J Mol Sci. 2021; 22(5).

PMID: 33799992 PMC: 7962069. DOI: 10.3390/ijms22052693.


Targeting Macrophages as a Potential Therapeutic Intervention: Impact on Inflammatory Diseases and Cancer.

Ponzoni M, Pastorino F, Di Paolo D, Perri P, Brignole C Int J Mol Sci. 2018; 19(7).

PMID: 29973487 PMC: 6073303. DOI: 10.3390/ijms19071953.


Application of liposomes in treatment of rheumatoid arthritis: quo vadis.

Kapoor B, Singh S, Gulati M, Gupta R, Vaidya Y ScientificWorldJournal. 2014; 2014:978351.

PMID: 24688450 PMC: 3932268. DOI: 10.1155/2014/978351.


Nanotherapeutic approaches for the treatment of rheumatoid arthritis.

Pham C Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011; 3(6):607-19.

PMID: 21837725 PMC: 3800699. DOI: 10.1002/wnan.157.


References
1.
Matsushima K, Oppenheim J . Interleukin 8 and MCAF: novel inflammatory cytokines inducible by IL 1 and TNF. Cytokine. 1989; 1(1):2-13. DOI: 10.1016/1043-4666(89)91043-0. View

2.
McCachren S, Greer P, Niedel J . Regulation of human synovial fibroblast collagenase messenger RNA by interleukin-1. Arthritis Rheum. 1989; 32(12):1539-45. DOI: 10.1002/anr.1780321207. View

3.
Claassen E . Post-formation fluorescent labelling of liposomal membranes. In vivo detection, localisation and kinetics. J Immunol Methods. 1992; 147(2):231-40. DOI: 10.1016/s0022-1759(12)80013-5. View

4.
Evequoz V, Trechsel U, Fleisch H . Effect of bisphosphonates on production of interleukin 1-like activity by macrophages and its effect on rabbit chondrocytes. Bone. 1985; 6(6):439-44. DOI: 10.1016/8756-3282(85)90221-2. View

5.
Johnson L, Yanch J . Absorbed dose profiles for radionuclides of frequent use in radiation synovectomy. Arthritis Rheum. 1991; 34(12):1521-30. DOI: 10.1002/art.1780341208. View